Solid Tumor Malignancy

Oncology
2
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Karyopharm Therapeutics
1 program
1
SelinexorPhase 1/21 trial
Active Trials
NCT05177276WithdrawnEst. Sep 2015
Chengdu New Radiomedicine
1 program
1
68Ga-NRT6020 InjectionPhase 11 trial
Active Trials
NCT06911489RecruitingEst. Dec 2027
PharmaEssentia
PharmaEssentiaMA - Burlington
1 program
HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in TaiwanN/A1 trial
Active Trials
NCT06665776Recruiting1,200Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Karyopharm TherapeuticsSelinexor
Chengdu New Radiomedicine68Ga-NRT6020 Injection
PharmaEssentiaHLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

Clinical Trials (3)

Total enrollment: 1,200 patients across 3 trials

Selinexor Combination Ph 1 Study

Start: Sep 2014Est. completion: Sep 2015
Phase 1/2Withdrawn

Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients

Start: Nov 2025Est. completion: Dec 2027
Phase 1Recruiting
NCT06665776PharmaEssentiaHLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan

Start: Mar 2023Est. completion: Dec 20251,200 patients
N/ARecruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 1,200 patients
3 companies competing in this space